Mark T. Iwicki
Known title: CHIEF EXECUTIVE OFFICERCIK: 0001415537
Associated companies
Transaction History
| KALA | ▼ Sell | Open Market | 154,894 | $125K | 10/23/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 13,227 | $53K | 6/24/2025 | View on chart |
| KALA | ▲ Buy | Grant | 2,450 | $0 | 6/15/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 10,866 | $41K | 6/3/2025 | View on chart |
| KALA | ▲ Buy | Grant | 22,100 | $0 | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 5,779 | $44K | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 15,168 | $72K | 6/26/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 7,392 | $45K | 5/31/2024 | View on chart |
| KALA | ▲ Buy | Grant | 14,300 | $0 | 1/4/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 4,539 | $31K | 1/4/2024 | View on chart |
| KALA | ▲ Buy | Grant | 158,873 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 71,715 | — | 5/31/2023 | View on chart |
| KALA | ▲ Buy | Grant | 41,700 | $0 | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Open Market | 198 | $6K | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Open Market | 561 | $4K | 10/26/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 7,975 | $3K | 6/27/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 9,518 | $12K | 1/4/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 27,598 | $50K | 10/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform
KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.